×

Regulus joins the race to cure Hep C

5:30 PM ET Mon, 9 Feb 2015

New data shows promise for Regulus Therapeutics' new Hep C drug. Kleanthis Xanthopopoulos, Regulus Therapeutics president and CEO, provides perspective on the clinical study, with CNBC's Meg Tirrell.